Novel medication targets for the treatment of alcoholism: Preclinical studies

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 2, 2012, Pages 151-162

  Rezvani, Amir H ^a   Lawrence, Andrew J ^b   Arolfo, Maria P ^c   Levin, Edward D ^a   Overstreet, David H ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Gilead Palo Alto Incorporated   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Alcohol intake; ALDH2 inhibitor; Carisbamate; CVT 10216; GS 455534; Inbred alcohol preferring rats; Inbred fawn hooded rats; JNJ 5234801; JNJ 39220675; RWJ 333369; Sazetidine A

Indexed keywords

1 [2,5 DIMETHOXY 4 IODOPHENYL] 2 AMINOPROPANE; ACAMPROSATE; ALDEHYDE DEHYDROGENASE ISOENZYME 2; ANXIOLYTIC AGENT; BUSPIRONE; CARISBAMATE; DAIDZIN; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; GS 455534; HISTAMINE H3 RECEPTOR ANTAGONIST; JNJ 39220675; JNJ 5234801; LAMOTRIGINE; N PHENYL 2 [1 [3 (2 PYRIDINYLETHYNYL)BENZOYL] 4 PIPERIDINE]ACETAMIDE; NALOXONE; NALTREXONE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3BETA4; NICOTINIC RECEPTOR ALPHA4BETA2; OPIATE RECEPTOR; OXIDOREDUCTASE INHIBITOR; SAZETIDINE A; SEROTONIN 2A ANTAGONIST; SODIUM CHANNEL; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; ZONISAMIDE;

ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ALCOHOLISM; ANXIETY; DESENSITIZATION; DETOXIFICATION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG TARGETING; DRUG TOLERANCE; ENZYME INHIBITION; FLUID INTAKE; FOOD INTAKE; HAMSTER; IN VITRO STUDY; LEARNING DISORDER; LOW DRUG DOSE; MEMORY DISORDER; MUSCLE RELAXATION; NEUROPATHIC PAIN; NONHUMAN; PATENT; PRIORITY JOURNAL; RELAPSE; REVIEW; SEDATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SLEEP DISORDER; TRANQUILIZING ACTIVITY;

EID: 84861747662     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912800673182     Document Type: Review

References (136)

1. Jupp B, Lawrence AJ. New horizons for therapeutics in drug and alcohol abuse. Pharmacol Ther 2010; 125: 38-168.
2. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 2009; 36:15-23.
3. Cowen MS, Lawrence AJ. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psych 1999; 23: 171-212.
4. Cowen MS, Rezvani AH, Jarrott B, Lawrence AJ. Ethanol consumption by Fawn-Hooded rats following abstinence: Effects of naltrexone and changes in opioid receptors density. Alcohol Clin Exp Res 1999; 23: 1008-14.
5. Kranzler JH, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25:1335-41.
6. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol: Clin Exp Res 2008; 32:1105-10.
7. Bell RL, Rodd ZA, Lumeng L, Murphy JM, McBride WJ. The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict Biol 2006; 11:270-88.
8. Li TK, Lumeng L, Doolittle DP. Selective breeding for alcohol preference and associated response. Behav Genet 1993; 23:163-70.
9. Rezvani AH, Overstreet DH, Janowsky DS. Genetic serotonin deficiency and alcohol preference in the Fawn-Hooded rats. Alcohol Alcohol 1990; 25: 573-5.
10. Overstreet DH, Rezvani AH, Cowen M, Cheng F, Lawrence AJ. Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment. Addict Biol 2006; 11: 356-73.
11. Rezvani AH, Overstreet DH, Cleves M, Parsian A. Further genetic characterization of the Fawn-Hooded (FH/Wjd) rat, an animal model of comorbid depression and alcoholism. Psychiatr Genet 2007; 17: 77-83.
12. Rezvani AH, Overstreet DH, Mason GA, Janowsky DS, Hamedi M, Clark J., et al. Combination pharmacotherapy: A mixture of small doses of naltrexone, fluoxetine, and a TRH analog reduces alcohol intake in three strains of alcohol preferring rats. Alcohol & Alcoholism 2000; 35:76-83.
13. Rezvani AH, Slade S, Wells C, Petro A, Lumeng L, Li TK, et al. Effects of sazetidine-A, a selective EE4442 nicotinic acetylcholine receptor desensitizing agent on both alcohol and nicotine self-Administration in selectively-bred alcohol preferring rats. Psychopharmacol 2010; 211:161-74.
14. Rezvani AH, Overstreet DH, Vaidya AH, Zhao B, Levin ED. Carisbamate, a novel antiepileptic candidate compound, attenuates alcohol intake in alcohol preferring rats. Alcohol Clin Exp Res 2009; 33-1366-73.
15. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004; 9:557-69.
16. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8:1445-9.
17. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 1992; 12: 2765-84.
18. Perry DC, Kellar KJ. [3H] epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J Pharmacol Exper Ther 1995; 275:1030-4.
19. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 2001; 21:1452-63.
20. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nature Neurosci 2005; 8:1465-70.
21. Lou AD, Wang A, Harding S, Juzytsch W, Shaham Y. Nicotine increases alcohol self-administration and reinstates alcohol seeking in rats. Psychopharmacol 2003; 168: 216-21.
22. Söderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 2000; 113: 85-96.
23. Blomqvist O, Engel JA, Nissbrandt H, Soderpalm B. The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur J Pharmacol 1993; 249: 207-13.
24. Blomqvist O, Erickson M, Johnson DH, Engel JA, Soderpalm B. Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur J Pharmacol 1996; 314: 257-67.
25. Farook JM, Lewis B, Gaddis JG, Littleton JM, Barron S. Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice. Pharmacol 2009; 83: 379-84.
26. Lou AD, Corrigall WA, Harding JW, Juzytsch W, Li TK. Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res 2000; 24:155-63.
27. Ericson M, Blomqvist O, Engel JA, Söderpalm B. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur J Pharmacol 1998; 358:189-96.
28. Nadal R, Chappell AM, Samson H. Effects of nicotine and mecamylamine microinjections into the nucleus accumbens on ethanol and sucrose self-administration. Alcohol Clin Exp Res 1998; 22: 1190-8.
29. Larsson A, Edström L, Svensson L, Söderpalm B, Engel JA. Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. Alcohol Alcohol 2005; 40: 349-58.
30. Tizabi Y, Copeland RL jr., Louis VA, Taylor RE. Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol Clin Exp Res 2002; 26:394-9.
31. Tizabi Y, Bai L, Copeland RL Jr., Taylor RE. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol 2007; 42: 413-6.
32. Steensland P, Simms JA, Holgate J, Jemma K, Richards, Barlett SE. Varenicline, an 4-2 nicotinic acetylcholine receptors partial agonist, selectively decreases ethanol consumption and seeking. PNAS 2007; 104:12518-23.
33. Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J of Neurosci 2010; 30:10169-76.
34. Ericson M, Löf E, Stomberg R, Söderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther 2009; 329: 225-30.
35. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 2009; 66: 185-90.
36. Rollema H, Hajos M, Seymore PA, Kozak R, Majchrzak MJ, Guanowsky V, et al. Preclinical pharmacology of the alph4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009; 78: 813-24.
37. Robles N, Sabria J. Ethanol consumption produces changes in behavior and hippocampal alpha7 and alpha4beta2 nicotinic receptors. J Mol Neurosci 2006; 30: 119-20.
38. Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, et al. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 2006; 70:1454-60.
39. Xiao Y, Yasuda RP, Sahibzada N, Horton L, DiPietro JR, Iwueze AF, et al. Pharmacological properties of sazetidine-A, a selective ligand of 4-2 nicotinic acetylcholine receptors, in Proceedings of the 38th Annual Meeting of the Society for Neuroscience 2008; Washington DC.
40. Levin ED, Rezvani AH, Xiao Y, Slade S, Cauley M, Wells C, et al. Sazetidine-A, a selective SS4442 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther 2010; 332: 933-9.
41. Overstreet DH, Kampov-Polevoy AB, Rezvani AH, Braun C, Bartus RB, Crews F. Suppression of alcohol intake by chronic naloxone treatment in P rats: Tolerance development and elevation of opiate receptor binding. Alcohol Clin Exp Res 1999; 23: 1761-71.
42. Rezvani AH, Overstreet DH, Levin ED, Rosenthal DI, Kordik CP, Reitz AB, et al. The Effects of atypical anxiolytic N-Phenyl-2-[1-[3-(2-pyridinylethynyl) benzoyl]-4-piperidine] acetamide (JNJ-5234801) on alcohol intake in alcohol-preferring P rats: Comparison with naltrexone. Alcohol Clin Exp Res 2007; 31:57-63.
43. Kuzmin A, Jerlhag E, Liljequist EJ. Effects of subunit selective nACh receptors on operant ethanol self-administration and relapselike ethanol-drinking behavior. Psychopharmacology 2009; 203: 99-108.
44. Greenbaum L, Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A, et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol Psychiatry 2006; 11: 312-22.
45. Kamens HM, Phillips TJ. A role for neuronal nicotinic acetylcholine receptors in ethanol-induced stimulation, but not cocaine-or methamphetamine-induced stimulation. Psychopharmacol 2008; 196: 377-87.
46. Rigbi A, Kanyas K, Yakir A, Greenbaum L, Pollak Y, Ben-Asher E, et al. Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes Brain Behav 2008; 7:164-72.
47. Schlaepfer IR, Hoft NR, Collins AC, Corley RP, Hewitt JK, Hopfer CJ, et al. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry 2008; 63:1039-46.
48. Löf E, Olausson P, deBejczy A, Stomberg R, McIntosh JM, Taylor JR, et al. Nicotine acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacol 2007; 195:333-43.
49. Breslin FJ, Johnson BA, Lynch WJ. Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacol 2010; 207-520-35.
50. Messiha FS, Butler D, Adams MK. Carbamazepine and ethanol elicited response in rodents. Alcohol 1986; 3:131-3.
51. Gardell LR, Whalen CA, Chambers MD, Boswell KJ, Hubbell CL, Reid LD. Valporate reduces intake of alcoholic beverage among rats. Behav Pharmacol 1998; 9: 638-9.
52. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361: 1677-85.
53. Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2009; 2:135-42.
54. Nguyen SA, Malcolm R, Middugh LD. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse 2007; 61:150-6.
55. Bisaga A, Evans SM. The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend 2006; 83: 25-32.
56. Rubio G, Lupez-Munoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disorder 2006; 8:289-93.
57. Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res 2007; 31:582-95.
58. Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsis 2006; 47:1822-9.
59. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69:273-94.
60. François J, Boehrer A, Nehlig A. Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia 2008; 49: 393-9.
61. Grabenstatter HL, Dudek FE. A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 2008; 49:1787-94.
62. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370:1915-22.
63. Colombo G, Vacca G, Serra S, Brunetti G, Garai MA, Gessa GL. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology 2003; 167:221-4.
64. Colombo G, Serra S, Vacca G, Carai MA, Gessa GL. Baclofeninduced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations. Eur J Pharmacol 2006; 550:123-6.
65. Maccioni P, Colombo G. Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. Alcohol 2009; 43:555-68.
66. Rezvani AH, Grady DR, Pucilowski O. Nimodipine, a Ca2+ channel antagonist, attenuates alcohol preference in alcohol preferring rats Drugs Develop 1993; 2:143-51.
67. Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm Jr RJ. Development of novel pharmacotherapies for the treatment of alcohol dependence: Focus on antiepileptics. Alcohol Clin Exp Res 2004; 28: 295-301.
68. Kordik CP, Luo C, Gutherman M, Vaidya AH, Rosenthal D, Crooke JJ, et al. Diarylacetylene piperidinyl amides as novel anxiolytics. Bioorg Med Chem Lett 2006; 16:3065-7.
69. Nutt D, Adinoff B, Linnoila M. Benzodiazepines in the treatment of alcoholism. Rec Devel Alcohol 1989; 7: 283-313.
70. Parkes H, Sinclair JD. Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats. Alcohol 2000; 21:215-21.
71. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT (2A receptors by agonists and antagonists. Brain Res Bull 2001; 56:441-51.
72. rd Annual Meeting of Society for Neuroscience 2003; Nov 8-12, Abst.# 959.6.5.
73. 2A antagonists amperozide and FG 5974. Alcohol Clin Exp Res 1997; 21: 1448-54.
74. Silvestre JS, Palacios JM, Fernandez AG, O'Neill MF. Comparison of effects of a range of 5-HT receptor modulators on consumption and preference for a sweetened ethanol solution in rats. J Psychopharmacol 1998; 12:168-76.
75. Christensen JC. Mechanism of the action of tetraethlthiuram disulfide in alcoholism: iron as an antidote for the TETD-alcohol reaction. Q J Stud Alcohol 1951; 12: 30-9.
76. Keung WM, Vallee BL. Daidzin and daidzein suppress free-choice ethanol intake by Syrian golden hamsters. Proc Natl Acad Sci USA 1993; 90:10008-12.
77. Keung WM, Vallee BL. Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. Proc Natl Acad Sci USA 1993; 90:1247-51.
78. Keung WM, Lazo O, Kunze L, Vallee BL. Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism. Proc Natl Acad Sci USA 1995; 92: 8990-3.
79. Keung WM, Klyosov AA, Vallee BL. Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters. Proc Natl Acad Sci USA1997; 94:16755:5.
80. Arolfo MP, Overstreet DH, Yao L, Fan P, Lawrence AJ, Tao G, et al. Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor. Alcohol Clin Exp Res 2009; 33:1935-44.
81. Liang JH, Chen F, Krstew E, Cowen MS, Carroll FY, Crawford D, et al. The GABAB receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcoholpreferring rats. Neuropharmacol 2006; 50: 632-9.
82. Overstreet DH, Knapp DJ, Breese GR, Diamond I. A selective ALDH-2 inhibitor reduces anxiety in rats. Pharmacol Biochem Behav 2009; 94:255-61.
83. Yao L, Fan P, Arolfo M, Jiang Z, Olive MF, Zablocki J, et al. Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat Med 2010; 16: 1024-8.
84. Lintunen M, Hyytiä P, Sallmen T, Karlstedt K, Tuomisto L, Leurs R, et al. Increased brain histamine in an alcohol-preferring rat line, and modulation of ethanol consumption by H3 receptor mechanisms. FASEB J 2001; 15: 1074-6.
85. Lintunen M, Raatesalmi K, Sallmen T, Anichtchik O, Karlstedt K, Kaslin J, et al. Low brain histamine content affects ethanol-induced motor impairment. Neurobiol Dis 2002; 9: 94-105.
86. Nuutinen S, Karlstedt K, Aitta-Aho T, Korpi ER, Panula P. Histamine and H3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacol 2009; 208: 75-86.
87. Panula P, Hyytia P, Karlstedt K, Kaslin J, Kiianmaa K, Lintunen M. Histamine H3 receptor confers alcohol intake in rodents. Annual Meeting Society for Neuroscience, Washington DC 2008.
88. Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H, Panula P. Distribution and modulation of histamine H3 receptors in basal ganglia and frontal cortex of healthy controls and patients with parkinson's disease. Neurobiol Dis 2001; 8: 707-16.
89. Pillot C, Heron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC, et al. A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neurosci 2002; 114: 173-93.
90. Pollard H, Moreau J, Arrang JM, Schwartz JC. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neurosci 1993; 52: 169-89.
91. Letavic MA, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, et al. Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development. Bioorg Medic Chem Lett 2010; 20: 4210-4.
92. Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Shoblock J, Motley T, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P. JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuserelated effects of alcohol in rats. Psychopharmacology 2011; 214: 829-841
93. Kozikowski, A.P., Musachio, J.L., Kellar, K.J., Xiao, Y., Wei, Z.-L. Ligands for nicotinic acetylcholine receptors, and methods of making and using them. WO000806 (2005).
94. Kozikowski, A.P., Musachio, J.L., Kellar, K.J., Xiao, Y., Wei, Z.-L., Fan, H. Ligands for nicotinic acetylcholine receptors, and methods of making and using them. US008030300 (2011).
95. Wu, J. Method for decreasing nicotine and other substance use in humans. US007341745 (2008).
96. Peters, D., Olsen, G.M., Nielsen, S.F., Nielsen, E. Ø. Azaring-ether derivatives and their use as nicotinic ACh receptor modulators. US006756386 (2004).
97. Mazurov, A.A., Klucik, J., Miao, L., Seamans, A.S., Phillips, T.Y., Schmitt, J.D., et al. 3-substituted-2-(arylalkyl)-1-azabicycloalkanes and methods of use thereof. NZ0565177 (2008).
98. Nielson, S.F., Peters, D., Nielsen, E.O., Olsen, G.M. Heteroaryl diazacycloalkanes, their preparation and use. US007064118 (2001).
99. Peters, D., Olsen, G.M., Nielsen, S.F., Nielsen, E. Ø. Certain heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors. US006825189 (2004).
100. Peters, D., Olsen, G.M., Nielsen, S.F., Nielsen, E. Ø. Heteroaryl diazacycloalkanes, their preparation and use. US006897219 (2005).
101. Schrimpf, M.R., Tietje, K.R., Toupence, R.B., Ji, J., Basha, A., Bunnelle, W.H., Daanen, J.F., Frost, J.M., Sippy, K.B. Diazabicyclic central nervous system active agents. US007598236 (2009).
102. Xie, W., Herbert, B., Ma, J., Nguyen, T.M., Schumacher, R., Gauss, C.M., Tehim, A. Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof. US007790722 (2010).
103. Asmussen, B., Hille, T., Hoffmann, H.-R., Opitz, K. Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism. WO48600 (2000).
104. Asmussen, B., Hille, T., Hoffmann H-R, Opitz K. Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism. US006627631 (2003).
105. Asmussen, B., Hille, T., Hoffmann, H.-R., Opitz, K. Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism. EP1154776 (2005).
106. Patent Holder. Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism. KR648767 (2006).
107. Madhat, M.N. Buccal and sublingual administration of physostigmine. US006264974 (2001).
108. Levay, G., Gacsalyi, I., Harsing, L.G., Simig, G. Combined pharmaceutical composition for the inhibition of the decline of cognitive functions. WO087212 (2005).
109. Buccafusco, J.J., Terry, A.V., Beach, J.W., Jonnala, R.R. Analogs of choline for neuroprotection and cognitive enhancement in neurogenerative disorders. US006881738 (2005).
110. Dey, D., Singh, G., Neogi, P., Ramachandran, U., Santhanagopalan, C. MAO A inhibitors with a diphenyl ether-substructure. WO030968 (2009).
111. Hilke, W. Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse. MX011249 (2005).
112. Hilke, W., Joachim, M., Klaus, O. Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse. KR006946 (2006).
113. Hilke, W., Joachim, M., Klaus, O. Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse. ZA0507213 (2006).
114. Mucke, H., Opitz, K., Moormann, J. Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments. CA2450787 (2002).
115. Opitz, K. Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments. MX011825 (2005).
116. Patent Holder. Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse. CA2523331 (2004).
117. Patent Holder. Combination of galantamine or desoxypeganine and substance with anti-excitatory action, use of composition (variants) for treating dependence on addictive substances or narcotics. UA0076753 (2004).
118. Winterhoff, H., Moormann, J., Opitz, K. Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse. WO096200 (2004).
119. Propes, M.J. Composition and method for treating alcoholism and other substance addictions. WO045641 (2008).
120. Propes, M.J. Composition and method for treating alcoholism and other substance addictions. US000005367 (2009).
121. Moormann, J., Mucke, H., Opitz, K. Active ingredient combination of e.g., galanthamine or deoxypeganine and e.g., acamprosate or memantine for treating an addiction such as alcoholism. WO102388 (2003).
122. Moormann, J., Mucke, H., Opitz, K. Active ingredient combination for treating an addiction such as alcoholism. SK0301565 (2004).
123. Moormann, J., Mucke, H., Opitz, K. Active ingredient combination of (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating narcotic or alcohol addiction. NZ0529944 (2007).
124. Moormann, J., Mucke, H., Opitz, K. Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments. CZ0299951 (2009).
125. Moormann, J., Mucke, H., Opitz, K. Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments. SK0287180 (2010).
126. Opitz, K., Moormann, J., Mucke, H. Active ingredient combination of e.g., galanthamine or deoxypeganine and e.g., acamprosate or memantine for treating an addiction such as alcoholism. AU2323873 (2006).
127. Bilbeny Lojo, N., Garcia Madrid, H., Font Arellano, M.B. Compounds used to treat alcoholism. WO004453 (2003).
128. Bilbeny Lojo, N., Garcia Madrid, H., Font Arellano, M.B. Compounds used to treat alcoholism. US007026514 (2006).
129. Bilbeny Lojo, N., Madrid, J.G. Amines as anti-alcoholism agents. US007232846 (2007).
130. Abelman, M., Organ, M., Zablocki, J., Keung, W.M., Tao, G. Quinazolinone derivatives as ALDH-2 inhibitors. US007951813 (2011).
131. Ilyuk, R.D., Krupitsky, E.M., Martyushin, S.V. Alcoholism recurrence preventing agent and method for the use thereof. WO031919 (2009).
132. Whitmire, D.R. Oral formulations for controlled release of alcohol deterrents. US006120806 (2000).
133. Ishikawa, S., Sato, N., Nagase, T., Tokita, S., Wada, T., Takahashi, H. Piperidine derivatives as histamine-H3 receptor antagonists. NZ0562766 (2011).
134. Keith, J.M. Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators. US007846930 (2010).
135. Kreutner, W. methods for the treatment of vascular disorders. US006472401 (2002).
136. Edgar, D.M., Hangauer, D.G., White, J.F., Solomon, M. Doxepin analogs and methods of use thereof. US007326721 (2008).